Alkermes (ALKS) announced overwhelming and surprising positive votes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, notes John McCamant, editor of The Medical Technology Stock Letter.
For further details see:
